Dept. of Biotechnology and Chemical Technology, Aalto University School of Chemical Technology, Aalto, Finland.
Biotechnol Prog. 2011 Nov-Dec;27(6):1588-98. doi: 10.1002/btpr.676. Epub 2011 Sep 23.
The total operating costs of small-scale monoclonal antibody production were calculated for two different upstream options and general downstream procedure based on protein A chromatography. The upstream options were a spin-filter equipped stirred-tank bioreactor (STR) and a hollow fiber bioreactor (HFB). Both the bioreactors were operated in perfusion mode. The total operating costs of the processes were 6,900 €/g for STR option and 6,400 €/g for the HFB option. In the both systems, the costs were dominated by expenses derived from the downstream section (almost 80%) that was almost identical in the both systems. In the upstream section, the investment depreciation was the largest cost item. The lower total costs of the HFB option were a result of lower investment costs and more concentrated product that led into savings also in downstream section. This study brings out the HFB as on viable alternative for stirred-tank bioreactor, especially in small-scale diagnostic monoclonal antibody production.
基于蛋白 A 亲和层析，我们分别计算了小规模单克隆抗体生产的两种不同上游选择方案和通用下游工艺的总运营成本。这两种上游选择方案分别是配备旋流过滤的搅拌槽生物反应器（STR）和中空纤维生物反应器（HFB）。两种生物反应器均采用灌流模式运行。STR 方案的总运营成本为 6900 欧元/克，HFB 方案的总运营成本为 6400 欧元/克。在这两种系统中，下游部分的费用（几乎占 80%）占据了主导地位，而且这两部分的费用几乎完全相同。在上游部分，投资折旧是最大的成本项目。HFB 方案总成本较低是因为投资成本较低，产品浓度较高，这也使得下游部分节省了成本。本研究表明，HFB 是搅拌槽生物反应器的一种可行替代品，特别是在小规模诊断单克隆抗体生产中。
